Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis

Table 4 Logistic multivariate regression to detect independent associations between anti-FOXE3p53-62 Ab levels and clinical and laboratory parameters (continuous and dichotomized) in 75 ACA⁺ patients

Variable	B coefficient	Exp (B)	P-value^a	95% CI
Gender	-0.065	1.067	0.956	0.104, 0.914
Age at diagnosis	-0.022	0.978	0.465	0.922, 1.038
Disease duration	0.039	1.040	0.661	0.943, 1.096
mRss	-0.06	0.942	0.277	0.846, 1.049
ESR	0.004	1.004	0.847	0.962, 1.049
CRP	-0.052	0.949	0.749	0.689, 1.307
ANA titer	0.000	1.000	0.550	0.999, 1.002
Anti-Ap1-17 IgG	0.00	1.000	0.678	0.999, 1.001
Anti-Ap17-30 IgG	0.108	1.114	0.035	1.007, 1.231
Disease severity score	0.138	1.148	0.315	0.977, 1.501
Disease activity index	-0.711	0.491	0.035	0.254, 0.950

^aA P-value >0.05 was not considered statistically significant. ACA, anti-centromere-associated protein antibodies; ANA, anti-nuclear antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; mRss, modified Rodnan skin score.

ISSN: 1478-6362